Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial.
about
Certolizumab pegol (CDP870) for rheumatoid arthritis in adultsSTAT6 and STAT1 Pathway Activation in Circulating Lymphocytes and Monocytes as Predictor of Treatment Response in Rheumatoid ArthritisEvaluation of disease activity in rheumatoid arthritis by Routine Assessment of Patient Index Data 3 (RAPID3) and its correlation to Disease Activity Score 28 (DAS28) and Clinical Disease Activity Index (CDAI): an Indian experience.Routine Assessment of Patient Index Data 3 score (RAPID3) correlates well with Bath Ankylosing Spondylitis Disease Activity index (BASDAI) in the assessment of disease activity and monitoring progression of axial spondyloarthritis.Monetary value of lost productivity over a five year follow up in early rheumatoid arthritis estimated on the basis of official register data on patients' sickness absence and gross income: experience from the FIN-RACo trial.Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA studyPhysical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegolApplying science in practice: the optimization of biological therapy in rheumatoid arthritis.Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low--results from RABBIT, the German biologics register.Rheumatoid arthritis in Saudi Arabia.Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trialPolymorphism at position +896 of the toll-like receptor 4 gene interferes with rapid response to treatment in rheumatoid arthritisSystemic lupus erythematosus in a multiethnic US cohort LUMINA (XLI): factors predictive of self-reported work disability.Work disability among two cohorts of women with recent-onset rheumatoid arthritis: a survival analysisKruppel-like factor 2 (KLF2) regulates monocyte differentiation and functions in mBSA and IL-1β-induced arthritisHead-to-head comparison of aggressive conventional therapy and three biological treatments and comparison of two de-escalation strategies in patients who respond to treatment: study protocol for a multicenter, randomized, open-label, blinded-assessoTwo-year results of disease activity score (DAS)-remission-steered treatment strategies aiming at drug-free remission in early arthritis patients (the IMPROVED-study)Evaluation of the effect of anti-tumor necrosis factor agent use on rheumatoid arthritis work disability: the jury is still out.Very early rheumatoid arthritis as a predictor of remission: a multicentre real life prospective studyWork in inflammatory and degenerative joint diseases.Discordance between patient and physician assessments of global disease activity in rheumatoid arthritis and association with work productivityWork disability in scleroderma is greater than in rheumatoid arthritis and is predicted by high HAQ scores.Optimal responses in disease activity scores to treatment in rheumatoid arthritis: Is a DAS28 reduction of >1.2 sufficient?Impact of etanercept tapering on work productivity in patients with early rheumatoid arthritis: results from the PRIZE study.Treatment of rheumatoid arthritis: a global perspective on the use of antirheumatic drugsPredictors and outcomes of sustained, intermittent or never achieving remission in patients with recent onset inflammatory polyarthritis: results from the Norfolk Arthritis Register.Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activityManagement of early aggressive rheumatoid arthritis during pregnancy and lactation.RAPID and FAST4WARD trials: certolizumab pegol for rheumatoid arthritis.Golimumab: a new anti-TNF-alpha agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.The value of early intervention in RA--a window of opportunity.Assessing the safety of biologic agents in patients with rheumatoid arthritis.Maximizing early treatment with biologics in patients with rheumatoid arthritis: the ultimate breakthrough in joints preservation.PROMs in inflammatory arthritis: moving from static to dynamic.Gene expression profiling of rheumatoid arthritis synovial cells treated with antirheumatic drugs.Welfare costs in patients with rheumatoid arthritis and their partners compared with matched controls: a register-based study.Effect of adalimumab on the work-related outcomes scores in patients with early rheumatoid arthritis receiving methotrexate.Response to methotrexate predicts long-term patient-related outcomes in rheumatoid arthritis.Declining needs for total joint replacements for rheumatoid arthritis.Goal-directed therapy for RA in routine practice is associated with improved function in patients with disease duration up to 15 years.
P2860
Q24193535-88155A4C-8BA4-4679-B4E5-3DA9C27D98A7Q28554987-364493C1-ED67-4F48-B6FF-CE1CB62FBBA2Q30566220-2F898401-ECAD-4451-83C8-7FB5DB22AF36Q30871532-3D97F769-E3DC-43B5-9F44-4BC59ABBD6E9Q31019080-6992E6B4-F3FD-40BF-837E-B3509ACD6BC3Q33540305-951A995F-0B08-4C48-AB8B-8BBAC559FCE3Q34117111-7DCF2A16-6D82-4DFA-A2FB-7B5E786B629FQ34613898-81FDD1DB-2AFA-4748-AAED-E6B066E372D3Q34897423-3F94927C-9BD0-452A-A9B4-88FBE1CE8812Q35183717-31EA531B-732B-481F-A052-869DDC83A6CCQ35351313-8C947BB3-8C09-4E3B-8751-6F7B921A0A48Q35637930-624CC372-3D40-4072-8CE8-5F9030525D78Q35638310-90698506-412C-4E38-B182-25E656AC6E7DQ35754388-88E85ECC-652A-44CE-98EC-B369E0C2CBC7Q35775909-CA9B244B-3605-4D76-8690-A77D04A70B69Q36334999-B79B4280-0BA1-4EC4-9E3B-4C03B8926753Q36485495-C14098BC-D07C-4643-9FB4-6780CA023A76Q36843031-11438322-B364-4835-975C-30487671FC70Q36876782-031B35D5-1846-465E-9213-EF8576734046Q36923056-28CC4288-92D8-40EE-8749-42EE9E341DE8Q36923257-69A1A70D-74C8-4EAC-8C2F-BE99A99936BFQ36985736-0C45B368-5231-4984-B9E3-0310AC3D3784Q37010967-B463D5D7-3DCB-4EB8-BDFC-FDECF7078BABQ37101040-ADEC9282-E30B-462B-9378-255C3F793294Q37147818-1BBB971C-CEE6-4032-AAE6-41CA3131099EQ37195347-C4DCF427-39EC-4EE9-A23B-1D59703D5B0EQ37347655-1FDCD5DC-22CA-4BC4-8833-D341C98C41B1Q37510901-A4AAF6C8-3070-446D-9615-EDD7C8CFBEDDQ37786625-6D5B4208-4C2D-498D-8F61-FC9ECD22BA18Q37786627-0506DF62-BB47-440E-A01A-580B0BF4B544Q37847069-AF5E7B73-24A7-4F62-9C1E-591CA7F6860FQ38020463-F2C298BC-9E25-4D3E-ABE0-8682C71DB6ACQ38072667-CAA85191-20E7-483A-8848-240EBCD55EC8Q38097709-0D83B781-7040-4BFD-9654-2733D40ADD11Q38303453-CC8E9EB4-1622-4F48-8DE2-7230B2AC36B5Q39248083-E4B5CA7C-96BD-44FD-B664-F04637DA82BFQ39821943-3FC4DD32-21ED-4FEE-B602-C2CE464678F4Q40884573-0BBE897D-57FE-4BB9-B351-A8511E70AD29Q42575975-43FDF301-865A-4D26-9977-684AAEFC31FFQ42578641-F901F0DE-E087-4154-8DFF-1D38BB620294
P2860
Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Early suppression of disease a ...... ience from the FIN-RACo trial.
@en
type
label
Early suppression of disease a ...... ience from the FIN-RACo trial.
@en
prefLabel
Early suppression of disease a ...... ience from the FIN-RACo trial.
@en
P2093
P2860
P356
P1476
Early suppression of disease a ...... rience from the FIN-RACo trial
@en
P2093
FIN-RACo Trial Group
Hannu Kautiainen
Jari Ahonen
Kari Puolakka
Marjatta Leirisalo-Repo
Markku Hakala
Markku Korpela
Pekka Hannonen
Pentti Järvinen
Sinikka Forsberg
P2860
P356
10.1002/ART.20716
P577
2005-01-01T00:00:00Z